A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus

Astellas

Status and phase

Completed

Phase 4

Conditions

Type 2 Diabetes Mellitus

Treatments

Drug: placebo

Drug: ipragliflozin

Study type

Interventional

Funder types

Industry

Identifiers

NCT02175784

1941-CL-0131

Details and patient eligibility

About

The purpose of this study is to assess the efficacy (superiority to placebo) of ipragliflozin based on the changes in HbA1C, as well as its safety, in patients with type 2 diabetes mellitus in combination with an insulin preparation once daily for 16 weeks. The long-term (52 weeks) safety and the persistence of the efficacy will also be evaluated.

Full description

This study consists of two parts. First part is a placebo-controlled multicenter, double-blind, parallel group study, in which subjects will receive ipragliflozin or placebo once daily in combination with an insulin preparation for 16 weeks. Second part is a multicenter, open-label period (36 weeks) with no placebo group. The dose of ipragliflozin can be doubled in combination with an insulin preparation during the second part.

Enrollment

262 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject has been diagnosed with type 2 diabetes mellitus for at least 12 weeks (84 days) at signing of informed consent.
Subject takes constant dosage and administration of insulin preparation for more than 6 weeks (42 days)
Subject has an HbA1C value between 7.5 and 10.0% at Visit 2 and the difference of HbA1C value within ± 1.0% between Visit 1 and Visit 2
Subject has a body mass index (BMI) 20.0 - 45.0 kg/m2

Exclusion criteria

Subject has type 1 diabetes mellitus
Subject has proliferative diabetic retinopathy
Subject has a history of clinically significant renal disease such as renovascular occlusive disease, nephrectomy and/or renal transplant
Subject has a history of recurrent urinary tract infection (more than three times within before 24 weeks of obtaining informed consent)
Subject has a symptomatic urinary tract infection or symptomatic genital infection
Subject has chronic disease which requires the continuous use of adrenocortical steroids and immunosuppressant (oral medication, injection, or inhalation)
Subject has a history of cerebral vascular attack, unstable angina, myocardial infarction, vascular intervention, and heart disease (NYHA Class III-IV) within 1 year (52 weeks) prior to Visit 1
Subject has unstable psychiatric disorder
Female subject who is currently pregnant or lactating, or who is possibly pregnant
Male and pre-menopausal female subject who cannot use an appropriate contraception during the study
Subject has severe infection, perioperative, or serious trauma
Subject has drug addiction or alcohol abuse
Subject has a history of malignant tumors (except for those who have not received treatment for malignant tumors for at least 5 years before informed consent acquisition and was not considered to have recurrence)
Subject has a history of an allergy with ipragliflozin and/or similar drugs (study drugs possessing SGLT 2 inhibitory action)
Subject has participated in another clinical study, post marketing study, or medical equipment study within 12 weeks (84 days) before providing written informed consent, or who is currently participating in any of those studies
Subject is unable, unwilling to adhere to compliances such as hospital visits and dose instruction specified in this study